THOUSAND OAKS, Calif.,
Dec. 11, 2017 /PRNewswire/
-- Amgen (NASDAQ:AMGN) today announced that the Amgen
Foundation has pledged $500,000 to
support victims of the Southern
California wildfires. Of this commitment, $200,000 will be directed to the United Way of
Ventura County to support their
immediate relief efforts. The Foundation has also committed up to
an additional $300,000 to support
victims of the Southern California
wildfires.
"These devastating fires have caused significant damage to our
communities and impacted our staff who live in them. We are
committed to assisting in relief efforts and are grateful for the
firefighters and first responders who have put their lives in
danger to protect our communities," said Cynthia M. Patton, chief compliance officer at
Amgen and chair of the Amgen Foundation Board of Directors.
"During this overwhelming time, we want our friends and
neighbors to know that we stand united with them now more than ever
and are grateful for the support from the Amgen Foundation," said
Eric Harrison, president and CEO of
United Way of Ventura County. "In
the days and weeks ahead, we will deploy more than $1 million that has been donated already to the
United Way Thomas Fire Fund to those who have experienced
devastation and heartache beyond measure."
The Amgen Foundation will also match donations made by Amgen
staff around the globe who wish to contribute their own funds to
qualifying Southern California
wildfire relief efforts.
About the Amgen Foundation
The Amgen Foundation seeks to advance excellence in science
education to inspire the next generation of innovators, and invest
in strengthening communities where Amgen staff members live and
work. To date, the Foundation has donated over $250 million to local, regional, and
international nonprofit organizations that impact society in
inspiring and innovative ways. The Amgen Foundation brings the
excitement of discovery to the scientists of tomorrow through
several signature programs, including Amgen Scholars, Amgen Biotech
Experience, and Amgen Teach. For more information, visit
www.AmgenInspires.com and follow us on Twitter
@AmgenFoundation.
About Amgen
Amgen is committed to unlocking the potential of biology for
patients suffering from serious illnesses by discovering,
developing, manufacturing and delivering innovative human
therapeutics. This approach begins by using tools like advanced
human genetics to unravel the complexities of disease and
understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages
its expertise to strive for solutions that improve health outcomes
and dramatically improve people's lives. A biotechnology pioneer
since 1980, Amgen has grown to be one of the world's leading
independent biotechnology companies, has reached millions of
patients around the world and is developing a pipeline of medicines
with breakaway potential.
For more information, visit www.amgen.com and follow us on
www.twitter.com/amgen.
Forward-Looking Statements
This news release contains forward-looking statements that are
based on the current expectations and beliefs of Amgen. All
statements, other than statements of historical fact, are
statements that could be deemed forward-looking statements,
including estimates of revenues, operating margins, capital
expenditures, cash, other financial metrics, expected legal,
arbitration, political, regulatory or clinical results or
practices, customer and prescriber patterns or practices,
reimbursement activities and outcomes and other such estimates and
results. Forward-looking statements involve significant risks and
uncertainties, including those discussed below and more fully
described in the Securities and Exchange Commission reports filed
by Amgen, including our most recent annual report on Form 10-K and
any subsequent periodic reports on Form 10-Q and Form 8-K. Unless
otherwise noted, Amgen is providing this information as of the date
of this news release and does not undertake any obligation to
update any forward-looking statements contained in this document as
a result of new information, future events or otherwise.
No forward-looking statement can be guaranteed and actual
results may differ materially from those we project. Our results
may be affected by our ability to successfully market both new and
existing products domestically and internationally, clinical and
regulatory developments involving current and future products,
sales growth of recently launched products, competition from other
products including biosimilars, difficulties or delays in
manufacturing our products and global economic conditions. In
addition, sales of our products are affected by pricing pressure,
political and public scrutiny and reimbursement policies imposed by
third-party payers, including governments, private insurance plans
and managed care providers and may be affected by regulatory,
clinical and guideline developments and domestic and international
trends toward managed care and healthcare cost containment.
Furthermore, our research, testing, pricing, marketing and other
operations are subject to extensive regulation by domestic and
foreign government regulatory authorities. We or others could
identify safety, side effects or manufacturing problems with our
products, including our devices, after they are on the market. Our
business may be impacted by government investigations, litigation
and product liability claims. In addition, our business may be
impacted by the adoption of new tax legislation or exposure to
additional tax liabilities. If we fail to meet the compliance
obligations in the corporate integrity agreement between us and the
U.S. government, we could become subject to significant sanctions.
Further, while we routinely obtain patents for our products and
technology, the protection offered by our patents and patent
applications may be challenged, invalidated or circumvented by our
competitors, or we may fail to prevail in present and future
intellectual property litigation. We perform a substantial amount
of our commercial manufacturing activities at a few key facilities,
including in Puerto Rico, and also
depend on third parties for a portion of our manufacturing
activities, and limits on supply may constrain sales of certain of
our current products and product candidate development. In
addition, we compete with other companies with respect to many of
our marketed products as well as for the discovery and development
of new products. Discovery or identification of new product
candidates cannot be guaranteed and movement from concept to
product is uncertain; consequently, there can be no guarantee that
any particular product candidate will be successful and become a
commercial product. Further, some raw materials, medical devices
and component parts for our products are supplied by sole
third-party suppliers. Certain of our distributors, customers and
payers have substantial purchasing leverage in their dealings with
us. The discovery of significant problems with a product similar to
one of our products that implicate an entire class of products
could have a material adverse effect on sales of the affected
products and on our business and results of operations. Our efforts
to acquire other companies or products and to integrate the
operations of companies we have acquired may not be successful. We
may not be able to access the capital and credit markets on terms
that are favorable to us, or at all. We are increasingly dependent
on information technology systems, infrastructure and data
security. Our stock price is volatile and may be affected by a
number of events. Our business performance could affect or limit
the ability of our Board of Directors to declare a dividend or our
ability to pay a dividend or repurchase our common stock.
CONTACT: Amgen, Thousand
Oaks
Kristen Davis, 805-447-3008
(Media)
Kristen Neese, 805-313-8267
(Media)
Arvind Sood, 805-447-1060
(Investors)
SOURCE Amgen